ASKA Pharmaceutical Holdings (4886) FY2027 Q1 Earnings Report

Quick View

Executive Summary

The first quarter resulted in decreases in both revenue and earnings, with the key takeaway being the substantial contraction in operating income and net income despite only a modest decline in revenue. Revenue was ¥173.8B (¥176.4B in the previous year, YoY -1.5%), operating income was ¥7.1B (¥14.6B in the previous year, YoY -51.4%), and ordinary income was ¥8.2B (¥15.9B in the previous year, YoY -48.7%). Net income attributable to owners of the parent was ¥5.3B (¥12.6B in the previous year, YoY -57.5%). The absence in the current period of the one-time ¥0.96B gain on the sale of fixed assets recorded in the previous year also amplified the earnings decline. The primary factors were a decline in overseas business revenue (-25.9%), a lower gross margin due to an unfavorable business mix (46.5%, down 240bp year on year), and negative operating leverage resulting from higher SG&A expenses (+3.0%).

Factors Affecting Business Performance

【Revenue】Revenue was ¥173.8B, down -1.5% year on year. The Pharmaceutical Business, which accounts for 83.3% of the revenue mix, was nearly flat at ¥144.8B (-0.2%). While the Animal Health Business grew to ¥19.5B (+6.0%), the Overseas Business declined substantially to ¥9.1B (-25.9%), becoming the primary factor behind the deterioration in the top line.

【Profit and Loss】Operating income was ¥7.1B (-51.4%). The gross margin declined by -240bp to 46.5% (48.9% in the previous year), while SG&A expenses increased to ¥73.8B (+3.0%) and the SG&A ratio rose to 42.4% (+180bp), resulting in negative operating leverage. By segment, operating income in the Pharmaceutical Business contracted to ¥11.3B (-33.3%), while the Overseas Business fell into a loss of ¥-0.3B. Ordinary income was ¥8.2B (-48.7%), with higher interest expenses (¥0.9B versus ¥0.5B in the previous year) and equity-method investment losses (¥0.6B) acting as downward factors. Net income attributable to owners of the parent was ¥5.3B (-57.5%), with the absence in the current period of the one-time ¥0.96B gain on the sale of fixed assets recorded in the previous year also amplifying the earnings decline. Both revenue and earnings decreased.

Segment Analysis

The Pharmaceutical Business generated revenue of ¥144.8B (83.3% of revenue, YoY -0.2%) and operating income of ¥11.3B (YoY -33.3%, margin 7.8%). Although it remains the primary earnings contributor, its margin declined significantly from the previous year. The Animal Health Business was the only segment to achieve revenue growth, with revenue of ¥19.5B (YoY +6.0%), but operating income was limited to ¥0.4B (YoY -65.6%, margin 2.3%), indicating that the revenue increase did not translate into higher earnings. The Overseas Business recorded revenue of ¥9.1B (YoY -25.9%) and operating income of ¥-0.3B (margin -3.9%), falling into the red and becoming a factor weighing on the group-wide margin. The Other segment was small, with revenue of ¥0.5B and an operating loss of ¥0.1B. The fact that even the revenue-growing segment did not achieve earnings growth highlights the need to review the cost structure.

Key Financial Indicators

【Profitability】The operating margin declined substantially to 4.1% (8.3% in the previous year), while the net margin fell to 3.1% (7.1% in the previous year). ROE was 0.7%, primarily due to the contraction in net income attributable to owners of the parent. 【Cash Flow Quality】Comprehensive income was ¥14.1B, exceeding net income of ¥5.3B; however, the difference was attributable to other comprehensive income, including a +¥8.0B valuation difference on securities and a +¥1.4B foreign currency translation adjustment, and does not indicate an improvement in cash-generation capacity. 【Investment Efficiency】Total asset turnover was low at 0.158x (quarterly), with inventories of ¥150.7B and accounts receivable of ¥165.9B weighing on asset efficiency. Goodwill was ¥23.4B, equivalent to 3.0% of net assets, indicating limited dependence on M&A. 【Financial Soundness】The equity ratio was 64.4% (62.6% in the previous year), and the current ratio was 289.2%, both high levels indicating sound short-term payment capacity. Interest-bearing debt (total short- and long-term borrowings) was ¥118.4B, while immediate coverage from cash and deposits of ¥71.1B (down -29.8% year on year) had declined from the previous year.

Cash Flow Analysis

As no statement of cash flows was disclosed, trends in funding are assessed based on changes in the balance sheet. Cash and deposits declined -29.8% to ¥71.1B from ¥101.3B in the same period of the previous year. Meanwhile, short-term borrowings increased to ¥41.6B (¥32.7B in the previous year, +27.3%), indicating a change in the funding mix. Inventories increased to ¥150.7B (¥147.4B in the previous year, +2.2%), and trade receivables increased to ¥165.9B (¥160.2B in the previous year, +3.5%), while accounts payable declined to ¥47.5B (¥52.9B in the previous year, -10.2%). The increase in working capital appears to have tied up funds. This accumulation of working capital is considered one factor behind the decline in cash and increase in short-term borrowings, making improvements in inventory management and the collection cycle for trade receivables key to future funding efficiency.

Earnings Quality

Current-period profit before tax of ¥8.2B was equal to ordinary income of ¥8.2B, and no extraordinary gains or losses were recorded. In the same period of the previous year, however, profit before tax was ¥16.9B versus ordinary income of ¥15.9B, reflecting the recognition of a ¥0.96B extraordinary gain from the sale of fixed assets. The disappearance of this temporary boost in the current period should be noted when making YoY comparisons. Non-operating income was ¥3.0B, primarily consisting of the stable income source of ¥1.8B in dividend income. Non-operating expenses totaled ¥1.9B, including interest expenses of ¥0.9B, up from ¥0.5B in the previous year, which pressured income at the ordinary income level. Comprehensive income was ¥14.1B, exceeding net income attributable to owners of the parent of ¥5.3B; the primary factor was the unrealized valuation gain of +¥8.0B on securities, which does not indicate an improvement in underlying earnings power.

Earnings Forecasts and Guidance

Q1 progress against the full-year company plan was 23.8% for revenue (¥173.8B/¥730.0B), 11.5% for operating income (¥7.1B/¥62.0B), 13.4% for ordinary income (¥8.2B/¥61.0B), and 11.1% for net income attributable to owners of the parent (¥5.3B/¥48.0B). Revenue progress was nearly in line with a simple pro rata assumption of 25%, but progress on earnings was substantially lower. Achieving the full-year plan will therefore depend on improvements in the gross margin and cost efficiency in the second half. The company disclosed that there was “none” for both revisions to its earnings forecast and dividend forecast, and it is maintaining its full-year plan at this time.

Shareholder Returns

The company forecasts an annual dividend of ¥65 per share. Based on the period-average number of shares outstanding of 2,839.6万 shares, the total annual dividend is approximately ¥18.5B. The payout ratio against the full-year net income plan of ¥48.0B is approximately 38.5%, and no revision to the dividend forecast has been made despite the slow progress in earnings during Q1. No disclosure regarding share repurchases was made, and shareholder returns are assessed solely on the basis of dividends.

Risk Factors

1. Deterioration in the Overseas Business: Revenue in the Overseas Business was ¥9.1B (YoY -25.9%), while operating income was ¥-0.3B, falling from a profit into a loss. The unfavorable mix was a factor weighing on the group-wide gross margin (-240bp), and its impact on profitability may continue.

2. Accumulation of Working Capital and Declining Cash-Generation Capacity: While inventories of ¥150.7B and trade receivables of ¥165.9B accumulated, cash and deposits declined to ¥71.1B (-29.8%) and short-term borrowings increased to ¥41.6B (+27.3%). Delays in improving funding efficiency could lead to additional funding requirements.

3. Higher Interest Burden and Equity-Method Losses: Interest expenses increased to ¥0.9B (¥0.5B in the previous year), while equity-method investment losses of ¥0.6B also pressured ordinary income. Interest rate trends on interest-bearing debt of ¥118.4B may affect ordinary income going forward.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (pharma)

Profitability and Returns

Both the operating margin and net margin are substantially below the industry median, placing the company in the lower tier of the industry in terms of profitability.

Growth and Capital Efficiency

The revenue growth rate is also substantially below the industry median, placing the company in the lower tier of the industry in terms of growth.

Source: Compiled by the Company

Key Points from the Earnings Report

1. Full-year progress rates were substantially below the simple pro rata benchmark of 25%, at 11.5% for operating income and 11.1% for net income. The degree to which earnings recovery can be achieved in the second half will be a key point to monitor in future earnings reports.

2. The one-time ¥0.96B gain on the sale of fixed assets recorded in the previous year did not recur in the current period. Accordingly, the composition from ordinary income through net income is closer to an underlying business-based result.

3. The fact that the revenue-growing Animal Health Business (+6.0%) did not achieve earnings growth, together with the Overseas Business falling into the red and weighing on the group-wide margin, are important points for assessing the earnings structure of the business portfolio.

Theoretical Share Price (Reference Value)

This is a mechanically calculated reference range based solely on publicly disclosed data using a residual income model (Ohlson-type model with an explicit 5-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥2,434–¥2,575 for a ±1% change in the cost of equity, and ¥2,495–¥2,508 for a ±0.1 change in ω.

Notes:

• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used; there is a timing difference from the full-year forecast.
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Model: Residual Income Model / Interest Rate Reference Month: 2026-06 / This value does not forecast or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was a weak start, with modest sales contraction translating into a disproportionate profit decline. Revenue fell 1.5% YoY to ¥17.38bn. Operating income declined 51.4% YoY to ¥0.71bn. Ordinary income fell 48.7% to ¥0.82bn. Profit attributable to owners of parent decreased 57.5% to ¥0.53bn, equivalent to EPS of ¥18.78. Gross profit decreased 6.3% to ¥8.09bn as cost of sales rose 3.1% despite lower revenue. The gross margin compressed by approximately 240bp YoY to 46.5%. SG&A expense increased 3.0% YoY to ¥7.38bn, producing negative operating leverage against the sales decline. Consequently, the operating margin fell by approximately 420bp to 4.1%, below the 5% operating-efficiency benchmark. Pharmaceutical operations remained the core business, contributing ¥14.48bn of revenue and ¥1.13bn of segment profit, but its segment profit fell 33.3% YoY. Animal health delivered 6.0% revenue growth, but segment profit fell 65.6%, while the overseas business moved into a ¥0.04bn segment loss as revenue declined 25.9%. Non-operating dividend income of ¥0.18bn supported ordinary income, although it did not offset the operating shortfall. The annualized ROE was only 2.8%, reflecting low profitability rather than excessive leverage. The balance sheet remains conservatively funded, with a 289.1% current ratio, 0.42x debt-to-equity ratio, and 13.3% debt-to-capital ratio. Management maintained its full-year forecast, which calls for 2.6% sales growth and 6.3% operating-income growth, implying a pronounced earnings recovery after the first quarter. Q1 progress against that forecast is behind the normal seasonal benchmark for profit, making recovery in pharmaceutical profitability, overseas operations, and cost absorption central to the full-year outcome.

Profitability Analysis

The reported annualized DuPont ROE is 2.8%, decomposed into a 3.1% net profit margin, 0.633x asset turnover, and 1.42x financial leverage. The principal constraint is the net margin, not balance-sheet leverage: financial leverage is restrained and asset turnover is modest for a pharmaceutical-led group with substantial investment securities, fixed assets, inventory, and intangible assets. Net margin weakened from the prior-year Q1 level implied by ¥1.26bn owner-attributable profit on ¥17.64bn sales to 3.1% this quarter, as profit fell far faster than revenue. Gross margin declined to 46.5% from approximately 48.9% a year earlier, a 240bp deterioration, indicating lower gross-profit conversion. Operating margin compressed to 4.1% from approximately 8.3%, or roughly 420bp, because the gross-profit decline was compounded by a 3.0% increase in SG&A. This negative operating leverage is the largest driver of the earnings decline. The pharmaceutical segment, the core business by operating-income contribution, generated a 7.8% segment margin versus approximately 11.7% in the prior-year Q1, and therefore accounts for much of the operating deterioration. Animal health's segment margin fell to 2.3% from 7.0%, despite sales growth, indicating sharply weaker cost absorption or mix. Overseas recorded a negative segment margin of 3.9%, compared with a positive 4.7% a year earlier. Unallocated corporate costs were broadly stable at ¥0.42bn, so the decline primarily arose within operating segments rather than from central-cost expansion. The 2.3% ROIC quality alert reinforces that returns on the capital base remain below the 5% warning threshold. Interest coverage of 7.65x remains sound, and the 1.149 interest burden indicates that non-operating income more than offsets interest expense at the pre-tax level. However, dividend income of ¥0.18bn represented 10.4% of revenue when combined with other non-operating income, and supported ordinary profit relative to EBIT; operating recovery is therefore more important than non-operating investment returns for sustainable earnings improvement.

Growth Assessment

Revenue declined 1.5% YoY, with broadly flat pharmaceutical sales unable to offset the 25.9% decline in overseas revenue. Pharmaceutical revenue declined only 0.2% to ¥14.48bn and remains the principal revenue base, representing 83.3% of consolidated sales. Animal health revenue rose 6.0% to ¥1.95bn, increasing its sales contribution, but its profit conversion deteriorated materially. Overseas revenue declined from ¥1.23bn to ¥0.91bn, reducing diversification and shifting the segment into loss. Other operations declined from ¥0.58bn to ¥0.38bn. Revenue quality is therefore currently dependent on stabilization and renewed growth in the domestic pharmaceutical franchise, given the small contribution and weaker profitability of other businesses. The full-year sales forecast of ¥73.0bn implies 2.6% YoY growth. Q1 sales progress is 23.8%, only 1.2 percentage points below the standard 25% Q1 pace and broadly consistent with the annual target. In contrast, Q1 operating-income progress is 11.5% against the ¥6.20bn full-year forecast, 13.5 percentage points below the standard pace. Ordinary-income progress is 13.4% against forecast, 11.6 percentage points below the standard pace. Owner-attributable profit progress is 11.1% against forecast, 13.9 percentage points below the standard pace. The unchanged guidance therefore embeds substantial margin recovery in subsequent quarters. Achieving the plan requires gross-margin restoration, containment of SG&A growth, normalization in animal-health profitability, and a turnaround in overseas operations. The low 2/10 consistency score also indicates limited demonstrated earnings consistency across the available period history.

Financial Health

Liquidity is strong, with current assets of ¥57.35bn against current liabilities of ¥19.84bn, resulting in a 289.1% current ratio and ¥37.51bn of working capital. The 213.1% quick ratio shows that liquidity remains ample even before relying on inventory liquidation. Cash and deposits of ¥7.11bn cover short-term loans of ¥4.16bn by 1.71x. Total interest-bearing debt is ¥11.84bn, comprising ¥4.16bn of short-term loans and ¥7.67bn of long-term loans. Short-term debt represents 35.2% of total interest-bearing debt, while current assets substantially exceed both current liabilities and short-term borrowing; maturity-mismatch risk is limited. Debt-to-equity of 0.42x, debt-to-capital of 13.3%, and liabilities equal to 29.7% of total assets indicate a conservative capital structure. Total equity increased to ¥77.30bn from ¥76.82bn a year earlier, supported by comprehensive income despite lower quarterly net income. Investment securities amount to ¥20.14bn, or 18.3% of total assets, leaving the balance sheet meaningfully exposed to market-value movements; valuation differences on securities contributed to comprehensive income in the quarter. Cash and deposits decreased 29.8% YoY to ¥7.11bn, while short-term loans increased 27.3% to ¥4.16bn. This combination warrants monitoring, although the absolute liquidity ratios and cash coverage remain robust. Goodwill of ¥2.34bn equals only 3.0% of equity and 2.1% of assets, while total intangible assets equal 7.8% of assets; M&A-related asset concentration and associated impairment exposure appear limited. The JGAAP framework requires amortization of goodwill, which can depress operating income relative to IFRS reporters, but goodwill is not large enough on the balance sheet to be a dominant capital-risk factor.

Notable B/S Changes

Cash & deposits: -¥3.02bn (-29.8% YoY) to ¥7.11bn - liquidity remains strong, but the reduction alongside increased short-term borrowing warrants monitoring. Short-term loans: +¥0.89bn (+27.3% YoY) to ¥4.16bn - short-term funding increased, although cash covers these borrowings by 1.71x and current assets comfortably cover current liabilities.

Cash Flow Quality

The working-capital profile is the primary cash-conversion concern. Reported receivable days of 87 exceed the 60-day quality-alert threshold, tying a substantial portion of the asset base to collections. Accounts receivable totaled ¥16.59bn, or 15.1% of total assets. Reported inventory-day alerts of 286 days and 148 days are both above their respective warning thresholds, indicating elevated inventory intensity under the reported measurement approaches. Inventories totaled ¥15.07bn, or 13.7% of total assets, and finished goods accounted for the full reported inventory balance. The reported cash conversion cycle of 327 days materially exceeds the 120-day alert threshold, indicating prolonged conversion of operating investment into cash. This lengthens funding requirements even though the group currently has strong liquidity. Inventory increased 2.2% YoY while revenue declined 1.5%, which points to weaker inventory turnover and raises the importance of monitoring demand realization, product mix, and inventory obsolescence. Receivables increased 3.5% YoY, also outpacing sales, consistent with the elevated DSO indicator. Trade payables decreased 10.2% YoY to ¥4.75bn, providing less supplier financing against the higher operating working-capital requirement. Electronic payables were ¥2.22bn and were broadly stable YoY. The cash-conversion-cycle alert is especially relevant for a pharmaceutical manufacturer because product inventories may be subject to expiration, demand changes, and production-planning risk. Improving collections and bringing inventory closer to sales demand would strengthen cash conversion and reduce reliance on balance-sheet liquidity.

Dividend Sustainability

The full-year dividend forecast is ¥65 per share. Against forecast EPS of ¥169.11, the implied dividend payout ratio is approximately 38.4%, below the 60% sustainability benchmark. The forecast payout is therefore moderate relative to expected earnings and supported by the company's strong equity base. Retained earnings of ¥62.98bn provide substantial accumulated capital support. The low 0.42x debt-to-equity ratio and strong liquidity metrics also limit financial-structure pressure on shareholder distributions. However, Q1 owner-attributable profit of ¥0.53bn represents only 11.1% of the ¥4.80bn full-year profit forecast, below the normal 25% quarterly pace. Dividend sustainability over the fiscal year consequently depends on delivery of the forecast earnings rebound rather than the first-quarter run rate. The long cash conversion cycle and elevated inventory and receivable days should remain under review because they may increase internal funding needs. The ¥65 forecast dividend corresponds to a meaningful increase from the prior-year Q1 indicated annual dividend level of ¥27 per share, so execution against the recovery plan is important for preserving payout flexibility. No total return ratio is calculated because the provided data do not identify a current buyback commitment.

Risk Assessment

Business risks include Pharmaceutical profitability risk: the core pharmaceutical segment's profit fell 33.3% YoY and its segment margin contracted to 7.8% from approximately 11.7%, making margin recovery the highest-impact operating issue., Overseas execution risk: overseas revenue declined 25.9% YoY and the segment shifted to a ¥0.04bn loss, exposing the group to demand, channel, foreign-exchange, and local-market execution volatility., Animal-health earnings volatility: revenue rose 6.0%, but segment profit declined 65.6%, indicating that sales growth is not presently converting into earnings., Pharmaceutical industry risk: product demand, reimbursement and drug-pricing revisions, competitive entries, and regulatory requirements can pressure sales and gross margins., Working-capital and inventory risk: reported inventory days of 286 and 148, together with a 327-day cash conversion cycle, increase exposure to inventory aging, demand forecasting errors, and cash absorption..

Financial risks include Cash-position risk: cash and deposits decreased 29.8% YoY while short-term loans increased 27.3%, although current liquidity and short-term-debt coverage remain strong., Investment-security valuation risk: investment securities represent 18.3% of total assets, so market-price movements can affect comprehensive income and equity., Return-on-capital risk: reported ROIC of 2.3% and annualized ROE of 2.8% are below relevant efficiency benchmarks, limiting internal compounding capacity if sustained., Forecast-delivery risk: Q1 operating-income progress was only 11.5% versus a standard 25% pace, requiring significant subsequent-quarter profit acceleration..

Key concerns include LOW_OPERATING_EFFICIENCY: the 4.1% EBIT margin is below the 5% warning level, caused by gross-margin compression and SG&A growth despite lower revenue; this weakens operating leverage and makes the full-year recovery plan more demanding., CAPITAL_EFFICIENCY: ROIC of 2.3% is below 5%, reflecting insufficient operating earnings relative to the invested asset base; this is particularly important given sizeable inventories, fixed assets, investment securities, and intangibles., HIGH_RECEIVABLE_DAYS: DSO of 87 days exceeds 60 days, suggesting slower collection or elevated credit tied up in customer balances; receivables grew while sales declined., HIGH_INVENTORY_DAYS: the reported 286-day and 148-day inventory indicators both exceed their warning thresholds; the implication is elevated stockholding and potential inventory aging risk, despite the different reported day-count measures., LONG_CCC: a 327-day cash conversion cycle exceeds the 120-day threshold, demonstrating that operating capital is converted to cash slowly; strong current liquidity mitigates near-term funding stress but does not remove the efficiency issue..

Investment Implications

Key takeaways include Q1 earnings deterioration was driven predominantly by margin compression and negative operating leverage, rather than by sales contraction alone., The pharmaceutical segment remains the core earnings engine, but its profit decline makes restoration of its gross and segment margins essential., Balance-sheet leverage and liquidity are strengths, with 289.1% current ratio, 0.42x debt-to-equity, and 7.65x interest coverage., The unchanged full-year plan requires a significant improvement from Q1 profitability, as operating-income progress trails the standard Q1 pace by 13.5 percentage points., Working-capital efficiency is a material monitoring issue because receivable and inventory days are elevated and the reported cash conversion cycle is long..

Metrics to watch include Pharmaceutical segment revenue growth and segment margin, Consolidated gross margin and SG&A-to-sales trend, Overseas segment return to profitability, Operating-income progress toward the ¥6.20bn full-year forecast, Receivable days, inventory days, and cash conversion cycle, Cash-and-deposits trend relative to short-term loans, Investment-security valuation movements and comprehensive income.

Regarding relative positioning, The company is financially conservative relative to the stated solvency benchmarks, but its current profitability and capital efficiency are weak relative to the stated pharmaceutical and broad-market operating benchmarks. Its modest goodwill and intangible-asset concentration reduce M&A balance-sheet risk, while elevated operating working capital and sub-5% operating margin are the principal relative weaknesses.